Background/Aims: Patients who are Helicobacter pylori antibody negative and have normal pepsinogen (PG) levels (group A of ABC (D) stratification) are considered unlikely to develop gastric cancer. This study aimed to clarify the involvement (uninfection, present infection or previous infection) of H. pylori in group A patients with early gastric cancer who underwent endoscopic submucosal dissection (ESD) by examining their background gastric mucosa endoscopically and histologically. Methods: This study included 166 patients with gastric cancer who were treated by ESD. Patients were classified according to PG levels and H. pylori antibody titers. Three biopsies (greater curvature of the antrum, lesser curvature of the middle corpus and greater curvature of the middle corpus) from group A were histologically analyzed and compared with those of groups B, C, D and after eradication). Results: In group A (34 patients), 32 patients had endoscopic atrophy (group A′). Histological neutrophil activity, chronic inflammation and atrophy scores were lower in group A′ than in other groups. Group A′ scores were similar to those of the after eradication group. Conclusion: Most of the group A patients with early gastric cancer were not uninfected with H. pylori, but had previous infections, thus carrying carcinogenic risk.

Journal Section:
Original Paper
Keywords:
ABC (D) stratification, Gastric cancer, Group A, Helicobacter pylori, Pepsinogen
1.
Helicobacter and Cancer Collaborative Group: Gastric cancer and Helicobacter pylori: a combined analysis of 12 case control studies nested within prospective cohorts. Gut 2001;49:347-353.
2.
Correa P: A new paradigm for human carcinogenesis. J Clin Gastroenterol 2000;30:341-342.
3.
Kakinoki R, Kushima R, Matsubara A, Saito Y, Okabe H, Fujiyama Y, Hattori T: Re-evaluation of histogenesis of gastric carcinomas: a comparative histopathological study between Helicobacter pylori-negative and H. pylori-positive cases. Dig Dis Sci 2009;54:614-620.
4.
Kato S, Matsukura N, Tsukada K, Matsuda N, Mizoshita T, Tsukamoto T, Tatematsu M, Sugisaki Y, Naito Z, Tajiri T: Helicobacter pylori infection-negative gastric cancer in Japanese hospital patients: incidence and pathological characteristics. Cancer Sci 2007;98:790-794.
5.
Matsuo T, Ito M, Takata S, Tanaka S, Yoshihara M, Chayama K: Low prevalence of Helicobacter pylori-negative gastric cancer among Japanese. Helicobacter 2011;16:415-419.
6.
Ono S, Kato M, Suzuki M, Ishigaki S, Takahashi M, Haneda M, Mabe K, Shimizu Y: Frequency of Helicobacter pylori-negative gastric cancer and gastric mucosal atrophy in a Japanese endoscopic submucosal dissection series including histological, endoscopic and serological atrophy. Digestion 2012;86:59-65.
7.
Mukoubayashi C, Yanaoka K, Ohata H, Arii K, Tamai H, Oka M, Ichinose M: Serum pepsinogen and gastric cancer screening. Intern Med 2007;46:261-266.
8.
Samloff IM: Cellular localization of group I pepsinogens in human gastric mucosa by immunofluorescence. Gastroenterology 1971;61:185-188.
9.
Samloff IM, Liebman WM: Cellular localization of the group II pepsinogens in human stomach and duodenum by immunofluorescence. Gastroenterology 1973;65:36-42.
10.
Nomura AM, Kolonel LN, Miki K, Stemmermann GN, Wilkens LR, Goodman MT, Perez-Perez GI, Blaser MJ: Helicobacter pylori, pepsinogen, and gastric adenocarcinoma in Hawaii. J Infect Dis 2005;191:2075-2081.
11.
Oishi Y, Kiyohara Y, Kubo M, Tanaka K, Tanizaki Y, Ninomiya T, Doi Y, Shikata K, Yonemoto K, Shirota T, Matsumoto T, Iida M: The serum pepsinogen test as a predictor of gastric cancer: the Hisayama study. Am J Epidemiol 2006;163:629-637.
12.
Kudo T, Kakizaki S, Sohara N, Onozato Y, Okamura S, Inui Y, Mori M: Analysis of ABC (D) stratification for screening patients with gastric cancer. World J Gastroenterol 2011;17:4793-4798.
13.
Kim HY, Kim N, Kang JM, Park YS, Lee DH, Kim YR, Kim JS, Jung HC, Song IS: Clinical meaning of pepsinogen test and Helicobacter pylori serology in the health check-up population in Korea. Eur J Gastroenterol Hepatol 2009;21:606-612.
14.
Di Mario F, Cavallaro LG, Moussa AM, Caruana P, Merli R, Maini A, Bertolini S, Dal Bó N, Rugge M, Cavestro GM, Aragona G, Plebani M, Franzé A, Nervi G: Usefulness of serum pepsinogens in Helicobacter pylori chronic gastritis: relationship with inflammation, activity, and density of the bacterium. Dig Dis Sci 2006;51:1791-1795.
15.
Fukao A, Tsubono Y, Tsuji I, Hisamichi S, Sugahara N, Takano A: The evaluation of screening for gastric cancer in Miyagi Prefecture, Japan: a population-based case-control study. Int J Cancer 1995;60:45-48.
16.
Ohata H, Kitauchi S, Yoshimura N, Mugitani K, Iwane M, Nakamura H, Yoshikawa A, Yanaoka K, Arii K, Tamai H, Shimizu Y, Takeshita T, Mohara O, Ichinose M: Progression of chronic atrophic gastritis associated with Helicobacter pylori infection increases risk of gastric cancer. Int J Cancer 2004;109:138-143.
17.
Watabe H, Mitsushima T, Yamaji Y, Okamoto M, Wada R, Kokubo T, Doi H, Yoshida H, Kawabe T, Omata M: Predicting the development of gastric cancer from combining Helicobacter pylori antibodies and serum pepsinogen status: a prospective endoscopic cohort study. Gut 2005;54:764-768.
18.
Mizuno S, Miki I, Ishida T, Yoshida M, Onoyama M, Azuma T, Habu Y, Inokuchi H, Ozasa K, Miki K, Watanabe Y: Prescreening of a high-risk group for gastric cancer by serologically determined Helicobacter pylori infection and atrophic gastritis. Dig Dis Sci 2010;55:3132-3137.
19.
Boda T, Ito M, Yoshihara M, Kitamura Y, Matsuo T, Oka S, Tanaka S, Chayama K: Advanced method for evaluation of gastric cancer risk by serum markers: determination of true low-risk subjects for gastric neoplasm. Helicobacter 2014;19:1-8.
20.
Miki K, Ichinose M, Kakei N, Yahagi N, Matsushima M, Tsukada S, et al: The clinical application of the serum pepsinogen I and II levels as a mass screening method for gastric cancer; in Takahashi K (ed): Aspartic Proteinases: Structure, Function, Biology, and Biomedical Implications. New York, Plenum Press, 1995, pp 139-143.
21.
Ichinose M, Miki K, Furihata C, Kageyama T, Hayashi R, Niwa H, Oka H, Matsushima T, Takahashi K: Radioimmunoassay of serum group I and group II pepsinogens in normal controls and patients with various disorders. Clin Chim Acta 1982;126:183-191.
22.
Miki K, Ichinose M, Shimizu A, Huang SC, Oka H, Furihata C, Matsushima T, Takahashi K: Serum pepsinogens as a screening test of extensive chronic gastritis. Gastroenterol Jpn 1987;22:133-141.
23.
Kimura K, Takemoto T: An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;3:87-97.
24.
Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M, Taniyama K, Sasaki N, Schlemper RJ: Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001;345:784-789.
25.
Dixon MF, Genta RM, Yardley JH, Correa P: Classification and grading of gastritis. The updated Sydney system. International workshop on the histopathology of gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161-1181.
26.
Kodama M, Murakami K, Okimoto T, Sato R, Uchida M, Abe T, Shiota S, Nakagawa Y, Mizukami K, Fujioka T: Ten-year prospective follow-up of histological changes at five points on the gastric mucosa as recommended by the updated Sydney system after Helicobacter pylori eradication. J Gastroenterol 2012;47:394-403.
27.
Strickland RG, Mackay IR: A reappraisal of the nature and significance of chronic atrophic gastritis. Am J Dig Dis 1973;18:426-440.
© 2016 S. Karger AG, Basel
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
2016
You do not currently have access to this content.